UPDATE: Baird Starts Centogene NV (CNTG) at Outperform

(Updated - December 3, 2019 8:01 AM EST)

(update comment)

Baird analyst Catherine Schulte initiates coverage on Centogene NV (NASDAQ: CNTG) with a Outperform rating and a price target of $15.00.

The analyst comments "Centogene utilizes clinical/genetic data to improve rare disease diagnosis/treatment. We believe its large patient database/biobank and diagnostic capabilities could position CNTG to be an attractive partner for pharma companies (note, our out-year revenue estimates assume success in signing additional partners). While we think the post-IPO sell-off has led to an overly discounted valuation, we do note caution in our outlook given limited visibility into new partnership timing/payments and CNTG's reliance on signing new partnerships to sustain growth longer term."

For an analyst ratings summary and ratings history on Centogene NV click here. For more ratings news on Centogene NV click here.

Shares of Centogene NV closed at $12.25 yesterday.

You May Also Be Interested In

• Northland Starts Bitfarms Ltd. (BITF) at Outperform
• City Holding (CHCO) PT Raised to $110 at Keefe, Bruyette & Woods
• Boston Scientific (BSX) PT Raised to $77 at Oppenheimer